Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5601054 | Chest | 2017 | 25 Pages |
Abstract
An ideal test, offering both accuracy and precision for measurement of any DOAC is not widely available. We recommend a dilute TT or ecarin-based assay for assessment of the anticoagulant effect of dabigatran and anti-Xa assays with drug-specific calibrators for direct Xa inhibitors. In the absence of these tests, TT or APTT is recommended over PT/INR for assessment of dabigatran, and PT/INR is recommended over APTT for detection of factor Xa inhibitors. Time since last dose, the presence or absence of drug interactions, and renal and hepatic function should impact clinical estimates of anticoagulant effect in a patient for whom laboratory test results are not available.
Keywords
PICTdRVVTISTHTEGDOACETPAPTTECTLC-MS/MSLaboratoryPulmonary embolismInternational Society on Thrombosis and HaemostasisThromboelastographyDeep venous thrombosisantithrombotic therapyactivated partial thromboplastin timethrombin timedilute Russell viper venom timeecarin clotting timeDirect oral anticoagulantDirect oral anticoagulantsAtrial fibrillationChestendogenous thrombin potentialAmerican College of Chest PhysiciansLiquid chromatography/tandem mass spectrometry
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Bethany T. MD, Adam MD, Deborah M. MD, Mark MD, David A. MD,